Bozhok A A, Semiglazov V F, Semiglazov V V, Arzumanov A S, Klettsel' A E
Vopr Onkol. 2005;51(4):434-43.
Recent data on prognostic and predictive significance of breast cancer-associated molecular markers are presented and their clinical value in making individual prognosis and choosing adequate therapy is discussed. Markers of tumor proliferation, steroid hormone receptors, factors of epidermal cell growth, plasminogen activators and inhibitors, factors influencing angiogenesis and apoptosis and genome characteristics are considered. It is concluded that only Ki-67, ER, PR and Her-2/neu may be recommended for clinical use.
本文介绍了近期有关乳腺癌相关分子标志物的预后和预测意义的数据,并讨论了它们在制定个体预后和选择适当治疗方法方面的临床价值。文中考虑了肿瘤增殖标志物、类固醇激素受体、表皮细胞生长因子、纤溶酶原激活剂和抑制剂、影响血管生成和细胞凋亡的因素以及基因组特征。得出的结论是,仅Ki-67、雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her-2/neu)可推荐用于临床。